Navigation Links
Genesis Pharmaceuticals Successfully Defends Itself in a Multi-Million Dollar Arbitration, Two Other Arbitration Proceedings Against Genesis are Withdrawn
Date:2/6/2009

Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, and granule form.

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

    Contact:

    Genesis Pharmaceuticals Enterprises, Inc.
    Ms. Elsa Sung, CFO
    Phone: (954) 727-8435
    E-mail: '/>"/>
SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Angiogenesis linked to poor survival in patients with rare type of ovarian cancer
2. Genesis Pharmaceuticals Enters Into Agreement to Purchase Hongrui Pharmaceuticals, and Acquire 22 New Traditional Chinese Medicines
3. Cardiogenesis Announces Successful Educational Symposium at Society of Thoracic Surgeons Meeting in San Francisco
4. What is the pathogenesis of C. jejuni-related disease?
5. ThermoGenesis Introduces New Cell Separation Technology for Veterinary Use at Major Equine Convention
6. ThermoGenesis Corp. Provides Updated Information for Conference Call/Webcast to Discuss Management Transition
7. ThermoGenesis Corp. Schedules Conference Call/Webcast to Discuss Management Transition
8. ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones
9. Organogenesis Receives Two Prestigious Awards for Economic Impact and Manufacturing Excellence
10. China West II Files Suit Against Genesis Pharmaceuticals and Capital Research Group Inc, Announces Conference Call Details
11. ThermoGenesis Reports First Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... “ ZeroWire ” was featured on NewsWatch as ... look at the latest and coolest technology products and ... for NewsWatch and a technology expert, conducted the review ... system and lifestyle management hub. , According to the ... burglaries in 2010. It goes without saying that home ...
(Date:4/21/2015)... Dallas, Texas (PRWEB) April 21, 2015 ... Review, H1 2015” provides comparative analysis on ... strengthens R&D pipelines by identifying new targets ... products. Complete report with TOC is available ... report also reviews key players involved in ...
(Date:4/21/2015)... NJ (PRWEB) April 21, 2015 ... across platforms and devices, today announced a new enhancement ... of the new Microsoft Office 365 Management Activity API. ... customers to fully audit and take action on all ... , “The new Office 365 Management Activity API provides ...
(Date:4/21/2015)... York, NY (PRWEB) April 21, 2015 ... of advanced delivery technologies and development solutions for ... the launch of ADVASEPT™ Lock, a stopper-less, glass- ... delivery of injectable medications. Easily opened, ADVASEPT Lock ... convenient and functional container closure with the security ...
(Date:4/21/2015)... 2015 The report “Dermatitis ... analysis on the therapeutic development for Dermatitis. ... identifying new targets and MOAs to produce ... TOC is available @ http://www.rnrmarketresearch.com/dermatitis-pipeline-review-h1-2015-market-report.html ... players involved in the therapeutic development for ...
Breaking Medicine News(10 mins):Health News:A Leader in Home Security was Featured on NewsWatch Television 2Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 2Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 3Health News:Catalent Announces the Expansion of its Advanced, Aseptic, Glass-Free Injectable Platform with New ADVASEPT™ Lock Delivery Technology 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4
... Smoking has been linked to a number of ... disorders, among others. Early smoking is shown to ... disorders (e.g., panic disorder, generalized anxiety disorder), and ... anxiety) increases the risk for later development of ...
... now become common place owing to the wide scale ... over again, scientists have been working on ways to ... results of a recent research have recently confirmed that ... diseases. ,The leeches have added to the ...
... A new study says that botulinum toxin can be useful ... trigeminal neuralgia. Botulinum or botox as it is popularly known ... and eye spasms. ,Researchers in Brazil and the United ... have detailed their findings in a study published in the ...
... Kollywood stars like Kamal Hassan, Chiranjeevi, Nagarjuna, Venkatesh, Vikram, ... to spread the awareness on AIDS. ,The show ... the Melinda and Bill Gates Foundation was an evening of ... anything in partnership with others. I am very proud of ...
... is likely to invoke the compulsory licensing (CL) provision ... //firms to produce and stockpile Swiss drug maker Roche’s ... against the most dreaded avian flu virus. , ... receipt of an application from the industry. Furthermore, the ...
... Abdominal wall hernias are one of the most common ... repairs// performed annually. Although ventral hernia repair (VHR) is ... problem. Wound infection has been identified as a consistent ... recent study, which appears in the November issue of ...
Cached Medicine News:Health News:Smokers Are Prone To Number Of Psychiatric Disorders 2Health News:Leeches Provide Clues Regarding The Prevention Of Heart Disease 2Health News:Predictors Of Wound Infection In Ventral Hernia Repair 2
(Date:4/21/2015)... -- Inmark,s acquisition of Saf-T-Pak last week positioned Inmark ... Division 6.2.  For over 25 years, Saf-T-Pak has ... on IATA, ICAO, US DOT, Transport Canada, RID/ADR ... were particularly interested in Saf-T-Pak,s proprietary Learning Management ... programs," said David Oyler , Inmark President ...
(Date:4/21/2015)... April 21, 2015 Global cap ... World demand for caps and closures will exceed $55 billion ... exceed two trillion annually. Beverages will continue to account for ... and a number of smaller markets are expected to register ... Although the most developed markets -- the US, ...
(Date:4/21/2015)... 2015 The global dermatology diagnostic devices market ... from 2014 to 2019. North America ... shares in the global dermatology diagnostic devices market. The ... mainly attributed to a wide range of factors, such ... dermatologists, and technological advancements made in the field of ...
Breaking Medicine Technology:Inmark's Acquisition Of Saf-T-Pak Results In Expansion Of Its Dangerous Goods Training Portfolio 2World Caps & Closures Market 2World Caps & Closures Market 3Dermatology Diagnostic Devices Market by Product, by End-User - Global Forecast to 2019 2Dermatology Diagnostic Devices Market by Product, by End-User - Global Forecast to 2019 3
... and NEW YORK, July 14, 2011 ... company leveraging its proprietary drug-delivery platforms to develop treatments ... announced that its lead product for oral mucositis, ... benefit network.  Reimbursement coverage for MuGard is now available ...
... BLUE BELL, Pa., July 14, 2011 Inovio Pharmaceuticals, ... in the development of therapeutic and preventive vaccines against ... cell and antibody responses were generated in its Phase ... for the prevention of avian H5N1 influenza delivered using ...
Cached Medicine Technology:Access Pharmaceuticals MuGard Added to CVS Caremark's Pharmacy Benefit Network 2Access Pharmaceuticals MuGard Added to CVS Caremark's Pharmacy Benefit Network 3Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 2Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 3Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 4Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 5Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 6Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 7Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 8Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 9
Inquire...
The autoclavable, aluminum needle box is designed to store loaded needles and help protect personnel from exposure. Each shield consists of an aluminum box with faceplate to match the grid pattern th...
... Brachytherapy loaders allow for efficient, easy ... Connectors to your customized plans at ... Bard loaders is the flexibility to ... in the QuickLoad™ Loader allows for ...
... designed to help you achieve one important ... procedure. All needles are engineered for exceptional ... for smooth entry and exit. A broad ... an ideal match with procedural needs and ...
Medicine Products: